VAXCYTE
Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide. The Company’s cell-free protein synthesis platform, comprising the XpressCFTM platform, exclusively licensed from Sutro Biopharma, Inc., together with Vaxcyte’s proprietary know-how, enables the design and production of protein carriers and antigens, the critical building blocks o... f vaccines, in ways that the Company believes conventional vaccine technologies currently cannot. In addition to its pneumococcal conjugate vaccines in development, VAX-24 and VAX-XP, Vaxcyte is leveraging its proprietary platform to advance other novel vaccines, including a prophylactic vaccine to prevent Group A Strep infections (VAX-A1) and a therapeutic vaccine to treat periodontal disease (VAX-PG).
VAXCYTE
Industry:
Biopharma Biotechnology Health Care
Founded:
2013-12-01
Address:
San Carlos, California, United States
Country:
United States
Website Url:
http://www.vaxcyte.com
Total Employee:
251+
Status:
Active
Contact:
650-837-0111
Email Addresses:
[email protected]
Total Funding:
2.35 B USD
Technology used in webpage:
Domain Not Resolving SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Cloudflare DNS WP Engine Smartsheet Dropbox Business
Similar Organizations
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Harmony Biosciences
Harmony Biosciences is a pharmaceutical company that develops and commercializes novel therapies for rare neurological disorders.
Kinarus Therapeutics (SIX:KNRS)
Kinarus is focused on developing novel treatments for patients suffering from serious viral, respiratory, and ophthalmic diseases.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Nodexus
Nodexus is democratizing access to live single cells for applications including gene editing, drug development, and more.
Halo Labs
Halo Labs is a biotechnology company that specializes in analytical instrumentation and biopharma.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
CARB-X
CARB-X investment in Grant - Vaxcyte
CARB-X
CARB-X investment in Grant - Vaxcyte
Pivotal bioVenture Partners
Pivotal bioVenture Partners investment in Series D - Vaxcyte
Longitude Capital
Longitude Capital investment in Series D - Vaxcyte
CTI Life Sciences Fund
CTI Life Sciences Fund investment in Series D - Vaxcyte
RA Capital Management
RA Capital Management investment in Series D - Vaxcyte
Roche Venture Fund
Roche Venture Fund investment in Series D - Vaxcyte
TPG Growth
TPG Growth investment in Series D - Vaxcyte
Foresite Capital
Foresite Capital investment in Series D - Vaxcyte
Janus Henderson Investors
Janus Henderson Investors investment in Series D - Vaxcyte
Key Employee Changes
| Date | New article |
|---|---|
| 2024-01-16 | Vaxcyte Appoints Whitney Jones as Chief People Officer |
| 2022-10-11 | Vaxcyte Expands Executive Leadership Team with Key Appointments |
| 2020-01-30 | SutroVax Announces Executive Appointment |
Official Site Inspections
http://www.vaxcyte.com Semrush global rank: 2.19 M Semrush visits lastest month: 9.16 K
- Host name: 141.193.213.21
- IP address: 141.193.213.21
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Vaxcyte"
About Us - Vaxcyte
Vaxcyte is a clinical-stage vaccine innovation company based in San Carlos, California with a unique ability to rapidly engineer, optimize and manufacture superior, high-fidelity vaccines at …See details»
Vaxcyte - Crunchbase Company Profile & Funding
Organization. Vaxcyte . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Vaxcyte is a next-generation vaccine company seeking to improve global health by developing superior and …See details»
Mission - Vaxcyte
At Vaxcyte, we are driven by our: Bold Goal. To prevent or treat infections caused by bacterial diseases, such as invasive pneumococcal disease, Group A Strep, periodontitis and Shigella. Sense of Urgency. Bacterial infections remain one …See details»
Vaxcyte - LinkedIn
Vaxcyte’s lead candidate, VAX-24, is a 24-valent, broad-spectrum pneumococcal conjugate vaccine being developed for the prevention of invasive pneumococcal disease. Vaxcyte | 10,896 followers on ...See details»
Vaxcyte, Inc.
(µ/ý X„„ :ûµ\F0G†› ÀÀÀŠ†Tèê4 È ¯ÅÚÖ–H ´E®X Ú$‰œ{ ûà& ý³þ4€ à7g«=n[/--ÙÊ|£ãÕy/iËœ"(%å O ‰ Ö»¶¡mn UègN¡Ïë yuï¾GŸ«îa»YªùêwÅ¡üíâ„¢Úõ§± Þ [Á³ Ö¹]ï¢JG¹¾üìݬ óG÷!ȳËŽ vNõ …See details»
VAXCYTE, INC. Company Profile | San Carlos, CA | Competitors ...
Find company research, competitor information, contact details & financial data for VAXCYTE, INC. of San Carlos, CA. Get the latest business insights from Dun & Bradstreet.See details»
Vaxcyte and Lonza Expand Collaboration for Global Commercial ...
Oct 16, 2023 Grant Pickering, Chief Executive Officer and Co-founder, Vaxcyte, commented: “Following the successful completion of our VAX-24 Phase 2 adult studies, and as we prepare …See details»
SutroVax Announces Name Change to Vaxcyte | Sutro Biopharma, …
Foster City, Calif., May 21, 2020 – SutroVax, Inc., a next-generation vaccine company, today announced that it has changed its name to Vaxcyte, Inc. The new name more accurately …See details»
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides ...
Nov 5, 2024 Vaxcyte, Inc.-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal …See details»
Vaxcyte Provides Positive Regulatory Updates on VAX-31
Nov 12, 2024 Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs ... Streptococcus pneumoniae is among the World Health Organization’s top …See details»
Decoding Vaxcyte Inc (PCVX): A Strategic SWOT Insight - Yahoo …
Nov 6, 2024 Vaxcyte Inc's financial overview for the nine months ended September 30, 2024, reveals a significant investment in research and development, totaling $343.03 million, up from …See details»
Fast-growing vaccine developer Vaxcyte doubles footprint at …
Nov 25, 2024 Vaxcyte this past summer also snapped up 38,200 square feet at 835 Industrial in a sublease from Cargo Therapeutics. Its stock, which closed at $88.54 per share on Friday, is …See details»
Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric …
Nov 12, 2024 Vaxcyte, Inc.-- VAX-31 Infant Indication: Investigational New Drug Application Cleared by FDA; Company Expects to Initiate VAX-31 Infant Phase 2 Study by the End of …See details»
PCVX.N - | Stock Price & Latest News | Reuters
Nov 22, 2024 Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its …See details»
Careers - Vaxcyte
Vaxcyte offers tremendous growth potential and is ripe with opportunities. For those willing to raise their hand there is enormous potential not only to directly shape the company but also to …See details»
Vaxcyte Announces $862.5 Million Public Offering - Cooley
Palo Alto – February 5, 2024 – Cooley advised Vaxcyte, a clinical-stage vaccine innovation company, on its $862.5 million follow-on public offering. Partners John McKenna and Mark …See details»
Vaxcyte - Vice President, Medical Affairs - jobs.lever.co
Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, which have serious and …See details»
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the
2 days ago Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants ... Streptococcus pneumoniae is among the World Health …See details»
Vaccine maker Vaxcyte doubles its space at Bay Area biotech …
Nov 27, 2024 In San Carlos, vaccine maker Vaxcyte has more than doubled its footprint since taking space at 825 Industrial Road, a new mega-campus that’s under development by …See details»
Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the …
1 day ago Vaxcyte, Inc.-- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series in Mid-2026, Followed …See details»